Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

Abstract

<b>Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile.</b> https://bit.ly/3SbisW3.